Clinical Trial Update: Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [Phase 3]

View source ↗

Summary

A Phase 3 trial of satavaptan for preventing recurrence of ascites in patients with ascites due to liver cirrhosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Liver Cirrhosis

Drugs mentioned

• Satavaptan (satavaptan)

Snippet

Sponsor: Sanofi | Conditions: Ascites, Liver Cirrhosis | Phase 3 | Status: TERMINATED